{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:07:39Z","timestamp":1793236059470,"version":"4.5.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This real-world retrospective cohort study evaluated utilization and comparative effectiveness of covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies in relapsed\/refractory mantle cell lymphoma (R\/R MCL) from electronic health records in the United States. Adults with R\/R MCL who received second- or third-line (2L\/3L) zanubrutinib, acalabrutinib, or ibrutinib monotherapy, on or after 1 January 2018, were included. Inverse probability of treatment weighting was used in adjusted Cox models to compare real-world time-to-next treatment (rwTTNT) and overall survival (rwOS). Among 698 patients who received 2L\/3L cBTKi monotherapy, 49%, 32%, and 19% received acalabrutinib, ibrutinib, and zanubrutinib, respectively. Unadjusted analyses showed median rwTTNT for 2L zanubrutinib, acalabrutinib, and ibrutinib was 14.5 (95% confidence interval [CI], 11.0-23.2), 12.8 (95% CI, 10.5-15.6), and 10.3 (95% CI, 7.6-13.7) months, and median rwOS was 26.4 (95% CI, 23.2 to not reached [NR]), 29.2 (95% CI, 22.9-38.1), and 29.3 (95% CI, 21.8-41.6) months, respectively. Median rwTTNT for 3L zanubrutinib, acalabrutinib, and ibrutinib was 21.1 (95% CI, 3.9 to NR), 9.2 (95% CI, 6.8-14.7), and 9.6 (95% CI, 4.8-18.0) months, and median rwOS was NR (95% CI, 27.3 to NR), 27.4 (95% CI, 15.1-42.2), and 27.0 (95% CI, 15.6 to NR) months, respectively. Adjusted models in the 2L\/3L cohorts combined showed numerically longer rwTTNT and statistically significantly longer rwOS for zanubrutinib vs ibrutinib (hazard ratio, 0.63; 95% CI, 0.42-0.96), and trends for improved rwTTNT and rwOS for zanubrutinib over acalabrutinib. Toxicity was a frequent reason for changing to another cBTKi. These findings suggest potential improvements in rwTTNT and rwOS with the use of second- and next-generation cBTKis for R\/R MCL from 2018 and beyond.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017160","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:11:50Z","timestamp":1763745110000},"page":"1457-1468","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel","family":"Phillips","sequence":"first","affiliation":[{"name":"1Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2617","authenticated-orcid":false,"given":"Mengyang","family":"Di","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7117-6124","authenticated-orcid":false,"given":"Taavy A.","family":"Miller","sequence":"additional","affiliation":[{"name":"3Flatiron Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Wang","sequence":"additional","affiliation":[{"name":"3Flatiron Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Pierre","sequence":"additional","affiliation":[{"name":"3Flatiron Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Maglinte","sequence":"additional","affiliation":[{"name":"4BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlene K.","family":"Seymour","sequence":"additional","affiliation":[{"name":"4BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"2","key":"2026030915513206900_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3747\/co.26.4345","article-title":"Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr Oncol"},{"key":"2026030915513206900_bib2","volume-title":"StatPearls","author":"Lynch","year":"2023"},{"issue":"suppl 1","key":"2026030915513206900_bib3","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1182\/blood-2023-190022","article-title":"Updated trends in incidence and survival of mantle cell lymphoma from 2000 to 2020","volume":"142","author":"Arora","year":"2023","journal-title":"Blood"},{"issue":"68","key":"2026030915513206900_bib4","doi-asserted-by":"crossref","first-page":"112516","DOI":"10.18632\/oncotarget.22367","article-title":"Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"2026030915513206900_bib5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023: featured updates to the NCCN Guidelines","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2026030915513206900_bib6","doi-asserted-by":"crossref","first-page":"e1019","DOI":"10.1016\/j.clml.2022.07.017","article-title":"Treatment landscape of relapsed\/refractory mantle cell lymphoma: an updated review","volume":"22","author":"Al-Mansour","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026030915513206900_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2017.10.004","article-title":"A systematic review of treatments of relapsed\/refractory mantle cell lymphoma","volume":"18","author":"Parrott","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026030915513206900_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026030915513206900_bib9","first-page":"53","article-title":"Zanubrutinib: a novel therapeutic option for the treatment of B-cell neoplasms","volume":"54","author":"Majeranowski","year":"2023","journal-title":"Acta Haematol Pol"},{"key":"2026030915513206900_bib10","unstructured":"National Comprehensive Cancer Network\n          . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). B-Cell Lymphomas. Version 1.2024. Updated 18 January 2024. Accessed 1 March 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"16","key":"2026030915513206900_bib11","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026030915513206900_bib12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3390\/jcm10061207","article-title":"Relapsed mantle cell lymphoma: current management, recent progress, and future directions","volume":"10","author":"Bond","year":"2021","journal-title":"J Clin Med"},{"key":"2026030915513206900_bib13","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.2147\/OTT.S155778","article-title":"Evaluating acalabrutinib in the treatment of mantle cell lymphoma: design, development, and place in therapy","volume":"12","author":"Girard","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2026030915513206900_bib14","unstructured":"BRUKINSA (zanubrutinib). Prescribing information. BeOne Medicines. 2023. Accessed 1 March 2024. https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2FPDF%2FBRUKINSAUSPI.pdf."},{"key":"2026030915513206900_bib15","unstructured":"CALQUENCE (acalabrutinib). Prescribing information. AstraZeneca. 2022. Accessed 1 March 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216387Orig2s000Correctedlbl.pdf."},{"issue":"11","key":"2026030915513206900_bib16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","article-title":"Clinical pharmacology and PK\/PD translation of the second-generation Bruton\u2019s tyrosine kinase inhibitor, zanubrutinib","volume":"14","author":"Tam","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"2026030915513206900_bib17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","author":"Eyre","year":"2022","journal-title":"Blood"},{"key":"2026030915513206900_bib18","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037143","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"7  2023","journal-title":"medRxiv"},{"key":"2026030915513206900_bib19","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2001.09765","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"13  2020","journal-title":"arXiv"},{"issue":"5","key":"2026030915513206900_bib20","doi-asserted-by":"crossref","first-page":"pkad058","DOI":"10.1093\/jncics\/pkad058","article-title":"Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022","volume":"7","author":"Guadamuz","year":"2023","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"2026030915513206900_bib21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026030915513206900_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood-2023-182942","article-title":"Multicenter study of mantle cell lymphoma outcomes following first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026030915513206900_bib23","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3324\/haematol.2022.282252","article-title":"Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis","volume":"108","author":"Di","year":"2023","journal-title":"Haematologica"},{"issue":"14","key":"2026030915513206900_bib24","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","article-title":"Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma","volume":"6","author":"Narkhede","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2026030915513206900_bib26","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/10428194.2018.1509320","article-title":"Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States","volume":"60","author":"Goyal","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2026030915513206900_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14737167.2023.2216458","article-title":"Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis","volume":"23","author":"Ito","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026030915513206900_bib28","author":"Food and Drug Administration","year":"2023"},{"issue":"21","key":"2026030915513206900_bib29","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026030915513206900_bib30","first-page":"343","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Le Gouill","year":"2024","journal-title":"Haematologica"},{"key":"2026030915513206900_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/CCI.20.00125","article-title":"Comparisons of real-world time-to-event end points in oncology research","volume":"5","author":"Walker","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"2026030915513206900_bib32","author":"Shah","year":"3-7  2022"},{"issue":"4","key":"2026030915513206900_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"2026030915513206900_bib34","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026030915513206900_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","article-title":"FDA approval summary: pirtobrutinib for relapsed or refractory mantle cell lymphoma","volume":"30","author":"Telaraja","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"36","key":"2026030915513206900_bib36","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.2217\/fon-2022-0976","article-title":"BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma","volume":"18","author":"Eyre","year":"2022","journal-title":"Future Oncol"},{"key":"2026030915513206900_bib37","first-page":"1","article-title":"New directions for mantle cell lymphoma in 2022","volume":"42","author":"Kumar","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2026030915513206900_bib38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"issue":"10441","key":"2026030915513206900_bib39","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"20","key":"2026030915513206900_bib40","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026030915513206900_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2024-199710","article-title":"Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: results from the international randomised controlled trial, ENRICH","volume":"144","author":"Lewis","year":"2024","journal-title":"Blood"},{"key":"2026030915513206900_bib42","unstructured":"A study to investigate the efficacy of zanubrutinib plus rituximab compared with bendamustine plus rituximab in adults with previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation (MANGROVE). ClinicalTrials.Gov identifier: NCT04002297. Updated 26 September 2025. Accessed 12 August 2025. https:\/\/clinicaltrials.gov\/study\/NCT04002297."},{"issue":"5","key":"2026030915513206900_bib44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2026030915513206900_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1457\/2505459\/blooda_adv-2025-017160-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1457\/2505459\/blooda_adv-2025-017160-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:51:41Z","timestamp":1773085901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1457\/548335\/Real-world-comparative-effectiveness-of-Bruton"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017160","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,25]]}}}